Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for Healthcare Professionals in Europe, Middle East and Africa. For disease awareness purposes only.

Think PH1 Logo

KNOW THE SIGNS OF PH1

Primary hyperoxaluria type 1 (PH1) has heterogeneous clinical manifestations.1 However, if you know what to look for, working towards a diagnosis can be straightforward.2,3

RECOGNISING THE SIGNS OF PH1

PH1 is a heterogeneous disease.1,4 PH1 patients with identical genotypes, and even members of the same family, can have variable disease symptoms.4

In infants and children

Infant and child patients may present with one or more of the clinical manifestations below:1,4–7

Haematuria Icon

Haematuria

Urinary Tract Infection Icon

Urinary tract infection

Child With Kidney Stone Icon

Stone passage

Chronic kidney disease

Infant Icon

Failure to thrive in infants

Dysuria Icon

Dysuria

Kidneys Icon

End-stage kidney disease (ESKD)

Abdominal Pain

Abdominal pain

Nephrocalcinosis Icon

Nephrocalcinosis

Family History Diagram of Kidney Stones/Kidney Disease Icon

Family history of stones/kidney disease

In adults

Patients may present with one or more of the clinical manifestations below:1,4–7

Recurrent Kidney Stones Icon

Recurrent kidney stones

Chronic kidney disease

Kidneys Icon

ESKD without history of stones

Unrecognized PH1 Symptoms Icon

History of unrecognised symptoms

Nephrocalcinosis Icon

Nephrocalcinosis

Family History Diagram of Kidney Stones/Kidney Disease Icon

Family history of stones/kidney disease

Kidney stones are the most common clinical manifestation and the one that most often leads to a diagnosis of PH1, though not all patients with PH1 may be stone formers.5,8,9 All patients suspected to have PH1 should undergo genetic assessment according to the ERKNet and OxalEurope guidelines 2023.10

REGARDLESS OF KIDNEY FUNCTION, ACUTE DECLINE CAN OCCUR SUDDENLY11,12

Though the course of PH1 is well characterised, with patients typically advancing toward ESKD, the rate of progression is variable.1,5,13 In some instances, kidney function can decline after a single incident of dehydration due to acute illness or intense physical activity.11,12,14-16 This can occur even in patients with previously stable disease.14

PH1 CAN BE LIFE-THREATENING, OFTEN DUE TO COMPLICATIONS OF ESKD AND/OR SYSTEMIC OXALOSIS1

Once the estimated glomerular filtration rate declines to below 30-45 mL/min/1.73 m2, systemic oxalosis can occur because the kidney is unable to excrete oxalate effectively due to excess accumulation of calcium oxalate crystals.5,6

Diagnose as soon as possible to ensure prompt management.1,2,3,6,19,20

ERKNET AND OXALEUROPE GUIDELINES 2023 RECOMMENDATIONS

ERKNet and OxalEurope guidelines 2023 recommend that all patients with suspected PH1 undergo genetic testing10

Zoe and Nathan’s Story With Primary Hyperoxaluria Type 1 (PH1)
“Zoe and Ryan (brother) were genetically tested following Nathan’s (brother) [PH1] diagnosis. At that time Zoe had no symptoms at all. We had no suspicion that there was anything wrong. The bloods were, it seemed ok, but her kidneys had a lot of kidney stones. How she was coping with that, I’ve got no idea.”

Becky

UK mother of two children with PH1

KIDNEY STONES MAY BE A SIGN OF SOMETHING MORE SERIOUS21

Recurrent kidney stones in an adult or any kidney stone in a child or adolescent could be a sign of a metabolic stone disease like PH1.21,22
Consider these patients for a full work-up and using genetic testing to help confirm PH1.21

Testing patients for PH1

See how genetic testing plays an important role in a PH1 diagnosis.1,3

Get Updates

Sign up to receive information from Alnylam about PH1

References: 1. Milliner DS, Harris PC, Cogal AG, Lieske JC. https://www.ncbi.nlm.nih.gov/books/NBK1283/. Updated February 10, 2022. Accessed October 2023. 2. Ben-Shalom E, Frishberg Y. Pediatr Nephrol. 2015;30(10):1781–1791. 3. Cochat P, Hulton SA, Acquaviva C, et al. Nephrol Dial Transplant. 2012;27(5):1729–1736. 4. Hoppe B. Nat Rev Nephrol. 2012;8(8):467–475. 5. Hoppe B, Beck BB, Milliner DS. Kidney Int. 2009;75(12):1264–1271. 6. Cochat P, Rumsby G. N Engl J Med. 2013;369(7):649–658. 7. Hopp K, Cogal AG, Bergstralh EJ, et al. J Am Soc Nephrol. 2015;26:2559–2570. 8. Edvardsson VO, Goldfarb DS, Lieske JC, et al. Pediatr Nephrol. 2013;28(10):1923–1942. 9. Hoppe B, Langman CB. Pediatr Nephrol. 2003;18:986–991. 10. Groothoff JW, Metry E, Deesker L, et al. Nat Rev Nephrol. 2023;19(3):194–211. 11. Cochat P. Kidney Int. 1999;55(6):2533–2547. 12. Leumann E, Hoppe B. J Am Soc Nephrol. 2001;12(9):1986–1993. 13. Jamieson NV. Am J Nephrol. 2005;25(3):282–289. 14. El-Reshaid K, Al-Bader D, Madda JP. Saudi J Kidney Dis Transpl. 2016;27(3):606–609. 15. Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Int J Nephrol. 2011;2011:864580. 16. Tintillier M, Pochet JM, Cosyns JP, Delgrange E, Donckier J. Clin Nephrol. 2004;62(2):155–157. 17. Falk N, Castillo B, Gupta A, McKelvy B, Bhattacharjee M, Papasozomenos S. Ann Clin Lab Sci. 2013;43(3):328–331. 18. Lorenz EC, Michet CJ, Milliner DS, Lieske JC. Curr Rheumatol Rep. 2013;15(7):340. 19. van Woerden CS, Groothoff JW, Wanders RJA, Davin JC, Wijburg FA. Nephrol Dial Transplant. 2003;18(2):273–279. 20. Raju DL, Cantarovich M, Brisson ML, Tchervenkov J, Lipman ML. Am J Kidney Dis. 2008;51(1):e1–e5. 21. Ferraro PM, D’Addessi A, Gambaro G. Nephrol Dial Transplant. 2013;28(4):811–820. 22. Hoppe B, Kemper MJ. Pediatr Nephrol. 2010;25(3):403–413.

PH1-CEMEA-00127 | November 2023

Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for Healthcare Professionals in Europe, Middle East and Africa. For disease awareness purposes only.

Welcome to the ThinkPH1.eu Healthcare Professional website.

By accessing the website, you confirm to be a Healthcare Professional from Europe, Middle East, or Africa:

If you are not a Healthcare Professional, please access the LivingwithPH1.eu website here.

You are now leaving ThinkPH1

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.